PetIQ Inc. (NASDAQ: PETQ) Q1 2022 earnings call dated May. 04, 2022
Corporate Participants:
Katie Turner — Investor Relations
McCord Christensen — Chief Executive Officer and Chairman of the Board
Zvi Glasman — Chief Financial Officer
Michael Smith — Executive Vice President, Products Division
Susan Sholtis — President
Analysts:
Stephanie Wissink — Jefferies — Analyst
Elliot Wilbur — Raymond James — Analyst
Jon Andersen — William Blair — Analyst
William B. Chappell, Jr. — Truist Securities — Analyst
John Lawrence — Benchmark — Analyst
Presentation:
Operator
Greetings, and welcome to PetIQ Incorporated First Quarter 2022 Earnings Conference Call and Webcast. [Operator Instructions] I would now like to turn the conference over to your host, Katie Turner, Investor Relations. Thank you, you may begin.
Katie Turner — Investor Relations
Good afternoon. Thank you for joining us on Pet IQ’s first quarter 2022 earnings conference call and webcast. On today’s call are, Cord Christensen, Chairman and Chief Executive Officer; and Zvi Glasman, Chief Financial Officer. Susan Sholtis, President; and Michael Smith, Executive Vice President of the Product division will also be available for Q&A.
Before we begin, please remember that during the course of this call, management may make forward-looking statements within the meaning of the federal securities laws. These statements are based on management’s current expectations and beliefs and involve risks and uncertainties that could differ materially from actual events or those described in these forward-looking statements. Please refer to the company’s annual report on Form 10-K and other reports filed from time to time with the Securities and Exchange Commission and the company’s press release issued today for a detailed discussion of the risks that could cause actual results to differ materially from those expressed or implied in any forward-looking statements made today.
Please note, on today’s call management will refer to certain non-GAAP financial measures, including adjusted gross profit, adjusted SG&A, adjusted net income and adjusted EBITDA. While the company believes these non-GAAP financial measures will provide useful information for investors, the presentation of this information is not intended to be considered in isolation or the substitute for the information presented in accordance with GAAP. Please refer to today’s release for a reconciliation of non-GAAP financial measures to the most comparable measures prepared in accordance with GAAP. In addition, PetIQ has posted a supplemental presentation on its website for reference. And with that, I’d like to turn the call over to Cord Christensen.
McCord Christensen — Chief Executive Officer and Chairman of the Board
Thank you, Katie, and good afternoon, everyone. We appreciate you joining us today to discuss our first quarter financial results. I’ll begin with an overview of our strategic business and financial highlights, then Zvi will review our financial results and outlook. Finally, Zvi, Susan, Michael and I will be available to answer your questions.
We are very pleased with our start to 2022. We reported first quarter net sales ahead of our expectations at $275.7 million representing an increase of 17.8% on a pro forma basis. We also generated another quarter of solid gross margin improvements. Adjusted EBITDA was $31.6 million and was also ahead of our guidance, resulting in adjusted EBITDA margin increase of 90 basis points year-over-year to 11.5%. The strength of our diversified pet products and services offering fueled these results.
The product segment posted record results, which were stronger than we expected as we benefited from broad-based growth across categories and sales channels with continued strength in our manufactured products and new product innovation. We also had $5 million of fill orders to support the start of the flea and tick season in the first quarter of 2022 that was anticipated to happen in second quarter of 2022. Today, Zvi will discuss more what we are seeing in the second quarter to date in the Product segment and highlight the consistent growth trajectory of our Products business in the context of our reiterated 2022 outlook and our view of our first and second half growth for the year.
Our services segment reported its best quarter since the onset of COVID in 2020, posting its fifth consecutive quarter of positive adjusted EBITDA on net revenue of $27.9 million. We remain pleased with the Services segment improvement, although we still have a lot of room for growth in future quarters for services to get back to pre-pandemic profitability. This year we’ve made modest assumptions for the Services segment as we work towards recovery in the segment’s growth and profitability over these next several quarters. We’ve created a unique business model committed to convenient and affordable pet health and wellness care. At PetIQ, we’re a purpose-built company addressing the large multi-billion dollar animal health market through our retail and e-commerce partners. We continue to be wherever pet parents choose to purchase their products with our animal health product portfolio and clinics including mass, grocery, club, pet specialty, pharmacy and online sales channels.
Focusing on our segment results in more detail, the product segment generated a solid start to the year with year-over-year net sales growth of 18.1% on a pro forma basis to $247.8 million. We generated double-digit sales growth across 5 of our top 7 manufactured product categories during the quarter. We continue to have the largest over-the-counter Animal Health brand portfolio with over 1,000 SKUs and a dominant market share in pet prescription products sold to retail and online. In addition, both our distributed and manufactured segments also saw double-digit growth despite a softer-than-normal start to the flea and tick season in the first quarter. Our manufactured OTC flea and tick growth rates continued a strong momentum into the new year growing 24% compared to Q1 last year. This growth was fueled by strong support of NextStar, our new premium flea and tick topical product launch, as well as strong contribution from the oral segment, which increased 37% compared to Q1 last year. Our Health and wellness portfolio also contributed another exceptional quarter as it continued to sustain strong year-over-year growth, up 36% compared to the prior year period. From a mix standpoint, our business in the quarter consisted of 73% distributed and 27% manufactured sales. As we look ahead, we believe PetIQ’s manufactured items can reach greater than 31% the product segment sales for 2022. we continue to participate in several of the largest and fastest-growing categories within the pet industry such as flea and tick solutions along with health and wellness.
Focusing on the category growth in more detail. For the 12 weeks ended March 26, 2022, the PetIQ portfolio gained a 130 basis points of share within the over-the-counter flea and tick category and now commands the number two market share position at a 19.7% total share of the market. This share gain was led by both PetArmor and CapStar, which both gained significant share over this timeframe. As for health and wellness, we continued our momentum in this high-growth segment as we picked up 32 basis points of share. The segment increased 7%, across the market, while our portfolio grew 9% for the 12 weeks ended March 26. From an R&D perspective, we had strong sell-through in the first quarter of a super premium health and wellness line we launched for a large club store operator during the fourth quarter. We expect an even greater benefit from this item in full year 2022 as our activation and support plans continue to play out in the second and third quarters.
We have also successfully launched Foster brand super premium health and wellness line this week. You can find it online at fosterpethealth.com. And as we discussed on our Q4 earnings call, we continue to be on track to introduce a direct-to-consumer initiative in the second half of 2022 as we continue to provide smarter options for pet parents to help enrich their pets’ lives through convenient and affordable access to veterinarian formulated products and services.
In terms of inflation, we have continued to experience cost inflation headwinds, particularly in labor. freight, raw materials and packaging. As a result, we implemented a price increase in Q4 across our manufactured product segment to offset most of these inflationary pressures. While these cost pressures have begun to stabilize, we are still evaluating if any further price action is required to offset in the balance of the year.
Now focusing on the Services segment, we generated another quarter of net revenue growth and positive adjusted EBITDA. We believe our service segment will make sequential and year-over-year improvements as we progress through 2022. In the quarter, we continue to optimize the Services segment to maximize the results and minimize disappointing our pet parents. First, we continued to adjust our clinic schedules to reduce labor hours and cancellations when labor is unreliable. Second we enhanced our retention recruiting programs which will support an increase in new wellness center openings in Q2 and for the balance of 2022.
During the quarter, our recruiting team hired 17 veterinarians. These new hires allowed us to open 4 new wellness centers and replaced unreliable temporary veterinarian labor in 13 existing wellness centers. We will continue to reduce the risk of deploying capital on new wellness centers, until we have all the necessary labor in place and optimize our existing centers to gain efficiencies and improve total performance of the segment. We remain prudent with our services growth near term, given the challenges in the vet labor market but have visibility to a large number of openings in the second quarter 2022 versus first quarter 2022.
Before I turn the call over to Zvi, on behalf of our Board of Directors and management team, and especially myself, I’d like to thank our President, Susan Sholtis. She has decided to leave PetIQ later this month to spend more time with her family in Indiana. Susan has been a tremendous asset and partner in helping to develop the strategies and operating procedures that help us build PetIQ. Over the last 4 years or contributions have been invaluable, including her leadership, guidance and support of our team throughout the pandemic. As we continue to grow our business, we will leverage the One IQ, smarter together culture, Susan helped us to create. Susan will continue to be available as needed to ensure a smooth transition through September.
Beginning June 1, Michael Smith, our EVP of the Products Division will assume the newly created role of President and Chief Operating Officer. I’m excited for Michael to take on this new role, he is a talented, collaborative leader with deep operational experience across pet and consumer packaged goods. Under his leadership since 2019, we have successfully delivered consistent growth in the product segment. His team has added $200 million of incremental products growth with a 3-year CAGR of greater of 17%. He has helped us successfully increase our manufacturing, scale, expand our product and brand diversity, as well as customer reach while capturing greater sales and profitability.
In closing, we believe our differentiated position in the animal health industry will continue to fuel our long-term growth along with robust industry tailwinds including increasing household penetration for pets, the humanization of pets and increasing pet population and more pet parents looking for convenience and affordable pet health and wellness. Our product and service teams executed well on our mission and we believe PetIQ is well positioned to continue delivering increases in our net sales and profitability as well as generate solid cash flow. With that overview, I would like to now turn the call over to Zvi.
Zvi Glasman — Chief Financial Officer
Thank you, Cord. We started off 2022 with strong and better than expected results compared to our Q1 guidance, nd we’re pleased with our team’s execution of our growth and efficiency initiatives. We generated solid growth on both the product and services segments helping us generate record net sales of $275.7 million, an increase of 17.8% on a pro forma basis. As Cord mentioned, we also experienced stronger than normal fill orders for the start of the flea and tick season that resulted in a shift of timing of approximately $5 million of sales to Q1, which were expected to occur in Q2 of this year.
First quarter gross profit increased 20.6% to $57.6 million resulting in a gross margin of 20.9%, an increase of 210 basis points from the first quarter of last year. Adjusted gross profit was $63.3 million, and adjusted gross margin was 23.6% for the first quarter of 2022, representing an improvement of 270 basis points year-over-year. This margin expansion reflects favorable product mix driven by the growth in sales of the company’s branded product portfolio, including our newly launched NextStar product. We also benefited from services segment optimization.
SG&A expenses for the first quarter of 2002 were $48.2 million compared to $40.7 million dollars in the first quarter of the prior year. Adjusted SG&A was $30.9 million for the first quarter of 2022 compared to $36.7 million in Q1 of last year. As a percentage of net sales, adjusted SG&A was 14.5%, a decrease of 20 basis points compared to the prior-year period. We are pleased with the leverage of our operating expenses, which was better than expected. We achieved this expense leverage even with a planned incremental $2.8 million dollars or 100 basis points of expense to support the launch of our two new brands and continued marketing investments to help accelerated growth of our manufactured brand product portfolio.
Our Q1 net income was $3.2 million, an increase of 32.4% resulting in EPS of $0.11. Adjusted net income was $18.3 million, an increase of 66% compared to the prior-year period. This resulted in adjusted EPS of $0.62 compared to $0.41 in the first quarter of 2021. Adjusted EBITDA was $31.6 million, an increase of 17.6% compared to $26.9 million in Q1 of last year. This was ahead of our guidance for Q1 of adjusted EBITDA of approximately $28 million. Adjusted EBITDA margin of 11.5% was 90 basis points higher than Q1 of last year. This solid improvement reflects the operating leverage generated in the quarter as a result of stronger margin on higher sales and the incremental profit.
Turning to our balance sheet and liquidity, as of March 31, 2022, the Company had cash and cash equivalent of approximately $51.1 million. During the first quarter, we generated approximately $16 million of operating cash flow, excluding working capital investments. We expect 2022 to be the strongest cash-generation year in the history of the company. Our long-term debt, which is comprised of our term loan, ABL and convertible debt facilities was $472.9 million as of March 31, 2022. In addition to our cash on hand at $51.1 million, the company has $100 million of availability on its revolving credit facility, representing total liquidity, which we define as cash on hand plus availability of $151 million as of March 31, 2022. We continue to believe our available liquidity, consistent growth, contribution from the product segment and improvement in the Services segment positions the company to drive free cash flow and build cash in the quarters ahead as well as opportunistically pay down our debt.
Now turning to our guidance. Based on our start to the year, we are pleased to reiterate our annual outlook for 2022 that we previously provided on March 1, 2022 and as we noted in today’s press release. Keep in mind that our annual outlook also assumes very little incremental adjusted EBITDA contribution from the Services segment. The Services segment has not returned to pre-pandemic levels when the business contributed approximately $10 million to $15 million in additional adjusted EBITDA. While we do expect to eventually return to pre-pandemic levels, based on what we are seeing in the veterinary labor markets, we believe it is prudent to assume the return will not occur in 2022. We continue to believe the Services business will be a key driver of long-term EBITDA and sales growth. However, until pandemic related dislocation in the labor market normalizes, we plan on a slower ramp in clinics as we take a more disciplined approach to capital allocation.
As demonstrated in 2021 and our 2022 guidance, and our modeling for 2023, due to the strength our Products business, we are confident that the company will continue to achieve strong growth despite the labor headwinds in the services business. From a seasonality perspective, we are updating our 2022 net sales outlook to reflect the shift in timing of $5 million in orders and sales, which occurred in the first quarter of 2022 from the second quarter of 2022 and a slower-than-normal start in the month of April of the flea and tick season, causing our customers to have inflated inventory levels at the start of the second quarter. However, beginning the last week of April, we experienced a more normalized trend to our seasonal flea and tick sales and our second quarter guidance assumes this trend will continue. With this in mind, we expect second quarter net sales of approximately $260 million. We expect Q2 adjusted EBITDA of approximately $28 million, Q2 adjusted EBITDA assumes adjusted SG&A as a percentage of net sales to be 340 basis points higher than the second quarter of 2021 at 17.5% due to an incremental $7 million or approximately 260 basis points of expense to support our two new manufacturing brand introductions and continued marketing investments to help accelerate the growth of our manufactured brands.
For the first half of 2022, we expect performing net sales to increase approximately 9% compared to the first half of 2021. We continue to expect most of the net sales growth in the second half of 2022 will be weighted towards the third quarter. In closing, we are pleased with our start to the year and remain optimistic about our growth in 2022 and beyond. We believe we have good visibility into our opportunities for growth and efficiency as our team continues to execute on our mission of delivering smarter options for pet care. With that, Cord, Susan, Michael and I are available for your questions. Operator?
Questions and Answers:
Operator
[Operator Instructions] Our first question comes from Steph Wissink with Jefferies. Please proceed with your question.
Stephanie Wissink — Jefferies — Analyst
Thank you. Good afternoon, everyone. We wanted to start with a question on bricks and mortar versus online for your manufactured brands specifically, but if you want to talk about in your portfolio in total, that would be helpful as well. Just wanted to understand a little bit about any change in business mix by channel.
McCord Christensen — Chief Executive Officer and Chairman of the Board
Thanks, Steph. Good to hear your voice. I’ve got Michael Smith with us today. Michael, would you like to address that?
Michael Smith — Executive Vice President, Products Division
Sure. Hey Steph, can you hear me?
Stephanie Wissink — Jefferies — Analyst
Yes. Can you hear you just fine.
Michael Smith — Executive Vice President, Products Division
Great. Yes. So I would say that we continue to see strong results in both our brick and mortars — brick and mortar partners business and our e-commerce channel. The one thing that will be unique in Q1 is that we did have a much stronger ship-out percentage to our brick and mortar partners because of the way that a pipeline for a strong support of a launch like NextSstar works in brick and mortar channel versus an e-com where there is not quite as much of a loan. So probably better to look at consumption trends versus shipments. And when we look at shipments we see — or I’m sorry, when we look at consumption, we see healthy share gain in both channels, but we’re seeing a greater share gain for our portfolio in the e-commerce customers versus the brick and mortar customers.
Stephanie Wissink — Jefferies — Analyst
That’s helpful, and it actually goes to my second question. Zvi, you talked about a step up in marketing in the second quarter, I know you’ve got some innovation. But is there any way to think about marketing mix or how are you thinking generally about your go-to-market strategy for some of your own innovation where you’re really driving category awareness and an uptick?
Zvi Glasman — Chief Financial Officer
Well, look…
McCord Christensen — Chief Executive Officer and Chairman of the Board
Steph, [Speech Overlap]
Zvi Glasman — Chief Financial Officer
Go ahead, Cord.
McCord Christensen — Chief Executive Officer and Chairman of the Board
I think Steph, I’ll take the first stab at it. The — typically and historically for our brands that we’ve matured and guidance that we are seeing consistent performance and they’re doing the work for us, we’re spending about 15% of sales to support those brands and we’ve had very good results as we’ve modified our efforts to continue quarter-over-quarter to gain share across all of those brands and couldn’t be happier with our performance. I think it’s an adequate spend in something you should consider as normal for our existing portfolio that’s in place, and with our blended margins of 55%, it gives us ample room to have contribution margin back the company and generate leverage at accretive EBITDA margin going forward in those brands as they grow. When we launched brands like NextStar or Foster or a new DTC initiative, and depending on the support we get from our customers and a bunch of different variables we make decisions on leaning in heavier the first year and then starting to pull that back over the out years as we see the performance of the idea we hope to stabilize into the similar rate.
This year we specifically had incredible support for NextStar with virtually all of our customers taking the item and getting significant distribution, and we see because of the margin profile of the item and the amount of placement that we got, that it was important for us to make sure we did a consumer awareness at a very significant level. So the $15 million we talked about, specifically $7 million in the second quarter, that’s really incremental marketing, we’re putting into new product launches. That’s money that was generated out of our existing portfolio sales that otherwise could have been brought to the profit or EBITDA line of the company to guarantee the success of those brands, and it’s an investment for the out years as we think those brands will perform well, become very stable in the categories and then eventually, get to where they’re back in line with that kind of 15% marketing spend then be very accretive in out years for the company. I hope that’s what you were asking about.
Stephanie Wissink — Jefferies — Analyst
Yes. It’s very helpful. Thank you very much. Thanks, Steph.
Operator
Our next question is from Elliot Wilbur with Raymond James. Please proceed with your question.
Elliot Wilbur — Raymond James — Analyst
Thanks. First question for Cord. Just want to ask you about price inflation trends in the distributed business. I know you’ve previously mentioned that you hadn’t seen price increases from some of the distributors along the lines — or some of the manufacturers were in line that you had expected, which seems a little bit surprising, I guess, in the context of the current environment. Wondering if that has changed at all over the past quarter?
McCord Christensen — Chief Executive Officer and Chairman of the Board
Yeah, we did have some of that change over the past quarter, and we have had some price increases come through from them, of which we’ve now delivered those price increases on to our customers, and they are timed to be in effect at the same time they take effect for us. And so, we’ve always had to philosophy to pass through those increases. I will tell you they have taken a more conservative approach to price increases than, I would say is normal across the market, we’ve seen. And again, some of it’s — the brands are more mature that have much higher margin profiles where some of these pharmaceutical brands are carrying 85% 90% margin based on them reading some of the economic situation has growing in the economy and the price points of their items, they opted to take some margin compression during this time versus taking the increases. So I would say we’ve seen about half of their portfolio receive pretty healthy price increases and the other half, which is in that category I just described, stay consistent with our current price structure.
So, no risk for us from a portfolio perspective. From a pricing or inflation standpoint, again, those are passed straight through and we’ve been doing that now for over 10 years and so it’s just part of natural and normal operating procedure.
Elliot Wilbur — Raymond James — Analyst
Okay. And then I’m going to shift gears and ask a couple of questions on the Services segment as well. Maybe if you could just provide some general color or commentary in terms of KPI performance in the quarter, expect $2 per clinic and in pets per clinic metrics. And then just thinking about the bigger picture here in terms of vet clinic trends, obviously, while data sources reporting has been a fairly significant slowdown in growth year-on-year, at least within sort of fixed-site locations. And at the same time, we’re looking at near record levels of debt services inflation. And just — how should — or how do you think of that? And how should we think of perhaps kind of those dynamics impacting your business model, which is a little bit more flexible, a little bit more value-oriented? I guess, thinking that — are you starting to see at the margin, what you call sort of a net benefit may be picking up share relative to traditional vet clinics based on some of these trends? Or you think the factor still most — did it play with respect to your business trends in the overall labor market?
McCord Christensen — Chief Executive Officer and Chairman of the Board
Yeah. I appreciate the question. It’s a great question, Elliot. I think first, I guess, we’ve told you guys along the way, through 2021, we saw cancellation rates around 25% for the full year due to labor issues that were going on. We had budgeted that same cancellation rate is 2022 and we are fortunate to report that, Q1 of this year we saw about a 20% improvement from where we had budgeted — or more like a 20% cancellation rate versus 25%. So the work we’re doing is getting better. From a KPI perspective our pets per clinic and our wellness centers are up 23% year-over-year from last year and running twofold pets more this year than we are running last year. Our community clinics are also running twofold pets more, which is a 15% increase over last year. And I think what we’ve seen is, we have had to take price and our average ticket is also up about 10%. Most of that is in line with what the pricing action we had to take to cover our cost increases with labor. And so, tickets up, pet counts up, all that’s up [Indecipherable] is down. I think what it really tells you is, we have a very narrow focused set of services that we do, we are very easily people in and out of there, whereas a lot of you read the commentary in the vet channel issue is they have a lot of complicated things they’re doing, the procedures they’re taking are taking longer. It’s slowing down, the time it’s taking is pushing people away. So I think where we have labor and we have clinics open, people are figuring out and understanding that where the — that the option of choice for their basic preventative care vaccinations and minor emergency-type stuff.
So we feel very good. We’re in the right place, right time with our model and the only really negative I can report is because of what went on through the pandemic level. We are — even though we’re 30% more clinics run in the wellness centers this year versus last year, and that being a positive number, we’re still gaining where we had our core base business running and we’re still negative to what we were in 2019 from a number of clinics run. So, we had a better quarter than we expected, made $1 million more than we expected in that business for the quarter. And I think all indications are, we’re in the right place, we just need to continue to hire more vets and get more clinics out there and get more recovery because the models right for what the consumer needs at the right time.
Elliot Wilbur — Raymond James — Analyst
Okay. And the, one last question for Zvi. Just wanted to go back to your comments last call with respect to the outlook for cash flow from operations. I think you had indicated you had expected a record year. Just wondering how things stand after first quarter, and maybe some specific commentary on just receivable and inventory trends in the quarter versus your original expectations. Thanks.
Zvi Glasman — Chief Financial Officer
Yeah. We’re on track. We were about negative $11 million of cash flow last year. We project we’re going to have $40 million to $50 million of positive cash flow this year. First quarter, we were up around $12 million cash flow year-over-year and all of that’s around working capital. So as we sit here today, we still expect to be $40 million $50 million of cash flow. Now the big variable is of course is if you have any shifts in working capital, but we feel really good about the current year cash generation. And moreover, as we think about the cash flow generation of the business potential longer term. we would note that there is a fair bit of investment in there, but eventually in newer to the benefit of cash flow. For example, we’re adding back 20-some-odd million dollars of wellness centers. So eventually when we get the wellness centers stabilized, that’s cash flow to the bottom line.
The EBITDA for the community clinics, we think to pre-pandemic levels, that’s another $10 million $15 million. And there’s a couple of other miss as well. So we’re really pleased with the cash flow generation potential for this year, moreover, longer term.
Operator
Our next question comes from Jon Andersen with William Blair. Please proceed with your question.
Jon Andersen — William Blair — Analyst
Hey. Good afternoon, everybody. I wanted to ask first the comments on the seasonality, or the change in seasonality for the year. Could you talk a little bit more about what caused the late start to the season in April? We’ve heard some similar commentary from, let’s say a lawn and garden manufacturer — product manufacturer that we cover. But what kind of drove that? And when the season starts later than it typically does, do you lose that business or is it typically shifted? So kind of how you’re thinking about the implications of that late start.
McCord Christensen — Chief Executive Officer and Chairman of the Board
Thanks for the question, Jon. And again, I think we watch a lot of key categories, suntan lotion, charcoal, lawn and garden, and in general, I think all of us had a lower — slower start to the season and knew what would be expected. And it really just tied to the weather that we saw across the country and weather patterns. And if I was going to be calling you in Chicago or other people in New York — I mean, we were seeing snow and even at our offices through the month of April — up even in the third week of April, we were seeing 3 and 4 inches of snow in a matter of a couple of days and just didn’t get that spring weather we typically get. And this is a category that the spring, sun kicks off the season. And so, this is one of those years that the weather was a little bit rougher in April. We did see a seasonal shift and saw that an uptick at that last week of April and these last few days of May that’s more in line with would be typical for the season.
We’ve been in this business over the last 12 years and we have found that the number of doses sold and the number of boxes sold is very consistent year-over-year. And if someone doesn’t treat themselves in April, it may happen in June, it may happen in July. A lot of the customers, there is a regimented person that’s using the product every single month for the year, and then there is that person that just on opportunistically use it as they need it for the season, they’r going to go out in the mountains. And they end up buying 1 to 1.5 boxes a year on average. And so, when they buy, we typically recover those sales.
So, I think as we said in our guidance, we need this trend to continue to meet the guidance that we put out there, and we believe it should based on past years history, and we believe that our full year guidance is intact because that we do believe we will recover those sales over the season, but it will be more weighted to the middle to end of the season based on what we’ve seen the start of the season.
Jon Andersen — William Blair — Analyst
Okay, that’s helpful. I wanted to ask about new products because it seems like it’s a big focus this year. From the Super Premium supplement at the club store, which is already launched to a couple of the other things you’ve mentioned in e-commerce initiative in the second half of the year, I guess NextStar. Could you — I guess, thinking about each of these, could you talk first about the kind of sell through you’re seeing with premium supplement at Club, because I think that’s important? You’ve talked about that being, I think, a $15 million revenue contributor this year, so initial sell-through and re-orders. And could you provide a little bit more detail on these other two items and what you’re seeing in terms of — or expecting in terms of distribution and whether there is any kind of early evidence of progress? Obviously, the second half initiative is something that we’re going to have to wait and see but even what that is and a little bit more color. Because, again, it seems like a really exciting year in terms of innovation.
McCord Christensen — Chief Executive Officer and Chairman of the Board
Yeah, I think we’re always pushing to innovate. Some years you just have all the right ideas hit at the right time and you get significant support from your customers and — the first comment I would tell you is we budgeted from all the initiatives this year to see about $30 million of topline contribution to the company. In that $30 million, we believe we will source about $10 million of that volume from ourselves. And so, see it through net gain of about $20 million for the year, which is not insignificant but in line with our total growth, about 25% of the new growth we will deliver for the full year. As far as performance, I’ll let Michael Smith comment. He has been the person to execute and build the customers and is closer to the way to measure that performance, and so I’ll let Michael comment on that part of it.
Michael Smith — Executive Vice President, Products Division
Yeah, happy to chime in. I think to the first one that you mentioned in terms of the super premium product with one of our large warehouse club retailers, that item’s been out for a period of time now where we’ve not only had the chance to read the merchants’ excitement from the proposition that we’ve built together. But now, we’ve also had a chance to see how their member perceived the item and happy to announce that that item is doing as expected, if not slightly better on the run rate that we’ve already established, and we still have, what I’d say is our largest push of activation or trial driving efforts yet to come. That program will have its biggest event in the back half of Q2. So the early read, very strong, yet still have some big activation plans yet to impact it.
On NextStar, I would say the same thing in terms of the feedback and engagement. And then the ultimate support that we got from our retail partners and the merchants that we engage in, they love the quality of the proposition, they’re hungry for innovation, we compete in a couple of categories, flea and tick being one that’s been pretty stale in terms of new news and meaningful innovation to the customer. So they’ve really jumped and hopped on board to support this initiative. Now, it’s technically been out in the market for 4 to 6 weeks, our large ACV and store count customers have just brought it in over the last 2 to 3 weeks. We have our first major promotional push coming at the end of this month along with our big investments in A&P hitting in May. So I would say, it’s still too early to get a great read on what the customer thinks of that proposition. But we haven’t gotten immense favorable support from our retail partners.
Jon Andersen — William Blair — Analyst
Great. That’s really helpful. I guess one for Zvi. This was asked earlier. Maybe I’ll ask in a different way. It’s been, I guess, a few years since you — couple of years since you’ve been free cash flow positive on a full year basis. And to the extent that you can address this, do you expect or plan to be free cash flow positive in 2022? Or is that something we should think about is a little bit longer-term longer out?
Zvi Glasman — Chief Financial Officer
Yeah, that — yeah, this is Zvi. That was a numbers I was speaking to. I was speaking to being $40 million to $50 million of free cash flow positive in ’22 with a longer term potential significantly higher than that as we build out our wellness centers and return to pre-pandemic levels and so forth.
Jon Andersen — William Blair — Analyst
Great. I just wanted to be sure I heard that correctly. Thanks so much, and good luck, everybody. Oh, and Susan, it’s been great conversing with you and spending time with you. Good luck in the future.
Susan Sholtis — President
Thank you, Jon.
Operator
Our next question comes from Bill Chappell with Truist Securities. Please proceed with your question.
William B. Chappell, Jr. — Truist Securities — Analyst
Yeah, thanks. Good afternoon.
McCord Christensen — Chief Executive Officer and Chairman of the Board
Hey, Bill.
William B. Chappell, Jr. — Truist Securities — Analyst
Just — and I’m — it might have been covered but on the $5 million pull forward, I guess maybe some more color why that happened. Was that a distributor business? Is it your own product? And then how much EBITDA went with that business in terms of quarter-to-quarter move?
McCord Christensen — Chief Executive Officer and Chairman of the Board
Yeah. So thanks Bill. The reality of it is, we’re negotiating when retailers are going to bring in the product and do the resets back in the fall. And typically, it’s accurate, and for the size of the business we are, $5 million is the biggest inter company change then we count ourselves lucky. But literally if a order we expected to ship in April that end up shipping in March came across the quarters because of how resets tied to the seasonality of when we load and the source of their inventory levels is brought up to meet to seasonal needs, the mix on that product was heavier towards our own product. Again, part of that’s the NextStar launch having significant fill order implications as well, and the EBITDA margin that we estimate that came forward into Q1 was $2 million.
William B. Chappell, Jr. — Truist Securities — Analyst
Great. And then the — just a — on Jon’s question on seasonality. So can you give us an update — I mean have you seen sell through pick-up in the month of April, early May as the weather has improved? And — so I’m just trying to understand like, from your commentary, do you expect the overall consumer takeaway to be a little bit lower just because you missed flowing the large per se, or is it too — I mean, it wasn’t that bad?
McCord Christensen — Chief Executive Officer and Chairman of the Board
Yeah. So the month of April is off, Bill, to historic efforts and we just did not see the consumer consumption that typically takes place. And a direct reflection of not seeing that consumption means we have inventory levels that are higher out there and the re-orders didn’t come as quickly as expected. And so, we believe that it was about a $20 million hit to the month of April, and to the quarter. When you look at our historical efforts, typically, once we see the season kick off the returns to normal efforts orders pick up and we do see it accelerate and you’ll see those doses and units picked up across the season still and we recover fully. We did see a change in the cadence of sales that took place the last week of April and these first few days of May. And so, our guidance reflects the impact that took place in April and the update, assuming that we are now back in the season and will run the rest of season, consistent with the normal budgets and that’s what’s involved in the guidance as we speak today. But we have again, left ourselves the ability to still be at our full year guidance based on past years and company history of recovering those doses in those units in the — during the total season.
William B. Chappell, Jr. — Truist Securities — Analyst
Great. Thanks for the color.
McCord Christensen — Chief Executive Officer and Chairman of the Board
Thanks, Bill.
Operator
Our next question is from John Lawrence with Benchmark. Please proceed with your question.
John Lawrence — Benchmark — Analyst
Yeah, thanks. Good afternoon, guys. Congratulations on the quarter.
McCord Christensen — Chief Executive Officer and Chairman of the Board
Thanks, John.
John Lawrence — Benchmark — Analyst
Cord, would you spend just a couple of minutes — obviously, what’s happening in the services business, the changes you made last fall to help that profitability a little bit — would you just dig into that a little bit? And Zvi, would you talk about maybe those line items and what’s happening on that labor side that’s generating a little better EBITDA performance there? And do you expect that to continue through the year?
McCord Christensen — Chief Executive Officer and Chairman of the Board
Yeah, I think John, obviously, we projected to have a similar performance full year as last year with not having visibility. That performance would have has us essentially covering all of the bills and necessary SG&A to support the business but having no positive EBITDA contribution to the company. First quarter, the efforts we’ve taken has allowed us to optimize the schedule, optimize our workflow and allowed us to not have as many times where we have staff show up and then not have a veterinarian present. So we have reduced wasting money. And ultimately, if we have veterinarians and staff there, we’re seeing more people when we do have it. So it’s really about just getting it right in this environment. I think the message we tried to let people know is, when we tell people we hired 17 vets and we used 13 of them to optimize the existing centers, and that’s at the core of it where we had unreliable temporary labor. Now, we get a W2 employee that is reliable, that’s more of a permanent fix that lets us continue to close that gap in that main issue. And so in the quarter, the efforts we took and the things we’re doing, allowed us to reduce the cancellation rate from 25% to 20%. And when we run 80% of the stores versus 75%, and you hear the pet counts are up 20%, wellness centers up 15% on that, and the average ticket’s up on average 10%, the ones we’re running are doing well. And so, it’s just about continued improvement, getting back to pre-pandemic clinic counts and continue to just execute our playbook. But lots of positive going on.
John Lawrence — Benchmark — Analyst
Great. Thanks. Susan, thanks for all the help, and good luck going forward.
Susan Sholtis — President
Thank you.
Operator
We have reached the end of the question-and-answer session. I’d now like to turn the call back over to management for closing comments.
McCord Christensen — Chief Executive Officer and Chairman of the Board
Appreciate everybody joining us today. Obviously, we had a exceptional first quarter as we saw a record sales and EBITDA and we’re definitely better than what we have guided as our performance and expected performance for the quarter. So we feel very fortunate to have a good start to this year. Coupled with that, we saw a rough April with the season starting late, which has allowed us to have time to reflect on how to get off through the season in a more condensed effort and put plans in place to recapture those sales and margin, but feel very good about our full year guidance and the Company’s performance and our positioning in the marketplace. We have lots of exciting new items and new opportunities out in the marketplace with the right investments coming at the right time to help support their growth and feel great about PetIQ’s position in the marketplace, especially when you have economically strained times. Being a low cost provider of healthcare for pets, we believe we’re well positioned for people looking to save money and our message should never be stronger than right now as we see an economy that’s fighting inflation, which has the option to then make major steps in towards our model that provides the same valuable serve, the same quality products at a much lower price. And so, we hope to reflect those numbers through the rest of the year and the performance and the consumer responding to this great offer we have as the company here at PetIQ. And just thank our people, our employees, all of our partners that helped us deliver the results, and thank all of you as our shareholders for supporting PetIQ, time and time again. And we look forward to talking to you very soon.
Operator
[Operator Closing Remarks]